Response to ensuring safety in cannabinoid prescriptions: A call for critical assessment
-
Published:2024-11
Issue:
Volume:88
Page:50
-
ISSN:0924-977X
-
Container-title:European Neuropsychopharmacology
-
language:en
-
Short-container-title:European Neuropsychopharmacology
Author:
Manning BrookeORCID,
Hayley Amie CORCID,
Downey Luke A
Reference5 articles.
1. Managing the high: developing legislation and detection methods for cannabis impairment;Arkell;Nature Reviews Neuroscience,2021
2. Ensuring safety in cannabinoid prescriptions: A call for critical assessment;Bueno;European Neuropsychopharmacology,2024
3. A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance;Manning;Journal of Psychopharmacology,2024
4. A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood;Manning;European Neuropsychopharmacology,2024
5. Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance;Narayan;Neurosci. Biobehav. Rev.,2022